Clinical efficacy of ozone therapy in managing category IIIB chronic prostatitis: symptom improvement and antioxidant...

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) significantly affects quality of life, particularly in its non-inflammatory Category IIIB form. Ozone therapy has shown promise in various chronic diseases but remains underexplored in CP/CPPS. This study aimed to evaluate the efficacy of ozone therapy in improving urinary symptoms, sexual function, psychological well-being, and overall quality of life in patients with Category IIIB CP/CPPS.

A retrospective analysis was conducted on 272 patients. The ozone therapy group (n = 152) received ten sessions of systemic major ozone therapy over five weeks, while the control group (n = 120) received no active treatment. Symptom severity and quality of life were assessed using validated clinical scales, and oxidative stress markers were measured at baseline and six weeks post-treatment.

Ozone therapy significantly improved clinical outcomes, reducing the International Prostate Symptom Score (22.95 to 11.38, p = 0.000) and the National Institutes of Health Chronic Prostatitis Symptom Index (25.34 to 15.88, p = 0.000), with significant improvements in pain, urinary symptoms, and quality of life subdomains. Additionally, the International Index of Erectile Function increased (15.30 to 20.88, p = 0.000), while the Aging Male Symptom Scale decreased (32.86 to 26.61, p = 0.000). Oxidative balance significantly improved, with Total Antioxidant Status increasing and Total Oxidant Status decreasing. Moreover, psychological well-being improved. In contrast, the control group showed minimal or no significant improvements.

These findings suggest that ozone therapy is safe, non-invasive, and effective treatment option for Category IIIB CP/CPPS, providing significant improvements in urinary symptoms, sexual function, quality of life, and psychological well-being, alongside a favorable shift in oxidative balance.